A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Proteinuria
- Focus Therapeutic Use
- Acronyms DIAMOND
- 25 Sep 2019 Planned primary completion date changed from 16 Jul 2019 to 1 Nov 2019.
- 25 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated